National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Voretigene neparvovec (Luxturna®) HTA ID: 19041

Voretigene neparvovec (Luxturna®) for the treatment of adult and paediatric patients with vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations and who have sufficient viable retinal cells.

 

NCPE Assessment Process Complete
Rapid review commissioned 24/09/2019
Rapid review completed 23/10/2019
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of voretigene neparvovec compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by the HSE 29/10/2019
Pre-submission consultation with Applicant 10/02/2020
Submission received from Applicant 03/04/2020
Preliminary review sent to Applicant 15/05/2020
NCPE assessment re-commenced 09/06/2020
Follow-up to preliminary review 26/06/2020
NCPE assessment re-commenced 10/07/2020
Factual accuracy sent to Applicant 26/08/2020
NCPE assessment re-commenced 03/09/2020
NCPE assessment completed 18/09/2020
NCPE assessment outcome The NCPE recommends that voretigene neparvovec (Luxturna®) is not considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments.*

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.